Drug Discovery Mass Spectrometry Market worth $1.69 billion by 2031
The report "Drug Discovery Mass Spectrometry Market by Component (Detector, Mass Analyzer, Ion Source, Vacuum System), Product (Triple Quad, Q-ToF, FTMS, Quad, ToF), Application (Biomarker, HTS, Proteomics), Installed Base & Replacement Rate - Global Forecasts to 2031" is projected to grow from USD 1.05 billion in 2025 and to reach USD 1.69 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 8.5% during the forecast period.
Browse 200 market data Tables and 80 Figures spread through 250 Pages and in-depth TOC on "Drug Discovery Mass Spectrometry Market by Component (Detector, Mass Analyzer, Ion Source, Vacuum System), Product (Triple Quad, Q-ToF, FTMS, Quad, ToF), Application (Biomarker, HTS, Proteomics), Installed Base & Replacement Rate - Global Forecasts to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/drug-discovery-mass-spectrometry-market-11784803.html
The drug discovery mass spectrometry market is expected to grow from USD 1.05 billion in 2025 to USD 1.69 billion by 2031, at a CAGR of 8.5% over this period. Mass spectrometry is now a key tool in early drug discovery because it offers higher accuracy than traditional analytical methods. Growth is driven by larger R&D pipelines for biologics & ATMPS, rising need for detailed analysis of structural details & multi-omics data, and higher demand for high-throughput screening, especially in Asia and other fast-growing regions.
The instruments segment dominated the market in 2025.
The instruments segment holds the largest share of the drug discovery mass spectrometry market because advanced MS platforms serve as the core analytical techniques for pharmaceutical, biotechnology, and CRO research environments. These systems are indispensable for high-sensitivity detection, precise mass measurement, and comprehensive structural characterization of small molecules, biologics, and emerging therapeutic modalities. The growing scale of screening programs and multi-omics initiatives is prompting labs to adopt high-resolution LC-MS/MS, Orbitrap, and Q-TOF systems, which offer improved throughput and durability. Continuous enhancements in hardware design, automation, and ionization performance make new-generation instruments significantly more appealing than older legacy platforms. The integration of MS with UHPLC, nanoLC, and microflow LC systems further reinforces their role as centralized, workflow-driven analytical solutions. Additionally, discovery teams are increasingly building in-house analytical capacity, driving capital investment toward versatile MS platforms rather than outsourcing key processes. The availability of pre-configured, application-specific instrument packages for DMPK, metabolite identification, and proteomics continues to fuel adoption. Together, these dynamics solidify mass spectrometry as the leading product category in the drug discovery market.
Proteomics and metabolomics dominated the market in 2025.
Proteomics and metabolomics studies usually account for the largest portion of the application sector in the drug discovery mass spectrometry market. The dominance is driven by rising use of high-resolution MS for extensive protein and metabolite profiling, as well as the growing need to comprehend disease mechanisms at the molecular level. MS is essential in functional biology and systems-level drug target discovery since proteomics and metabolomics rely significantly on LC-MS and HRMS technologies to provide high sensitivity, precise mass detection, and extensive coverage. This application field has grown crucial to early-stage R&D as biopharmaceutical companies build their pipelines for biologics and precision medicine. Furthermore, proteomics and metabolomics continue to be the primary source of market revenue due to the fast growth of multi-omics research, biomarker validation studies, and advanced therapeutic development, including cell and gene therapies.
North America is expected to hold the largest share of the drug discovery mass spectrometry market during the forecast period.
North America is expected to hold the largest share of the drug discovery mass spectrometry market because of the region's high concentration of pharmaceutical and biotechnology firms that continuously invest in cutting-edge analytical technologies. The region benefits from well-established drug development pipelines, high R&D spending, and widespread adoption of high-resolution mass spectrometry platforms across proteomics, metabolomics, and biologics research. Adoption is further accelerated by top universities, CROs, and research institutes through large-scale initiatives funded by federal agencies. Furthermore, a developed regulatory framework in North America promotes the use of accurate analytical instruments for safety, effectiveness, and quality evaluation in preclinical and early-stage research. The region's robust clinical research networks, quick integration of automation and AI-driven workflows, and the existence of significant MS manufacturers all contribute to the region's dominant market position.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Drug Discovery Mass Spectrometry Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
